Optimal Adult Vyvanse Dosing for ADHD
Start adults with Vyvanse at 30 mg once daily in the morning, then titrate by 20 mg weekly increments until optimal response is achieved, with a typical effective dose range of 30-70 mg/day and a maximum FDA-approved dose of 70 mg/day. 1
Starting Dose and Titration Protocol
The FDA label provides clear guidance for adult dosing:
- Initial dose: 30 mg once daily in the morning 1
- Titration schedule: Increase by 20 mg per week until symptoms are adequately controlled 1
- Target dose range: 30-70 mg/day (all three doses—30,50, and 70 mg—demonstrated superior efficacy compared to placebo in controlled trials) 1, 2
- Maximum approved dose: 70 mg/day 1
Evidence for Dose-Response Relationship
Clinical trials demonstrate that all three FDA-studied doses (30,50, and 70 mg) are effective, with some nuances:
All doses work, but higher doses may provide additional benefit for some patients. In the pivotal adult trial (Study 7), all three doses showed statistically significant improvement over placebo on the ADHD Rating Scale, with mean reductions of -16.2, -17.4, and -18.6 points for 30,50, and 70 mg respectively (vs -8.2 for placebo) 2. While the differences between doses weren't statistically significant in that study, exploratory dose-response analyses suggest patients with greater baseline symptom severity, particularly hyperactive-impulsive symptoms, may benefit more from higher doses 3.
The effect sizes are substantial across the dose range. In the workplace simulation study, medium-to-large effect sizes (0.5-0.8) were maintained from 2 to 14 hours post-dose, demonstrating sustained efficacy throughout the workday and into evening hours 4.
Clinical Decision-Making Algorithm
Week 1: Start 30 mg once daily in the morning after baseline assessment (blood pressure, pulse, height, weight) 5
Week 2-4: If inadequate symptom control, increase to 50 mg. Assess response using:
- Patient self-report of ADHD symptoms (inattention, hyperactivity-impulsivity)
- Functional impairment in work/social domains
- Side effect profile (appetite, sleep, cardiovascular effects)
Week 5+: If still inadequate response at 50 mg, increase to 70 mg. Document that lower doses were insufficient and higher dose is well-tolerated.
Maintenance: Once optimal dose achieved (typically 4 weeks), continue with monthly monitoring initially, then quarterly once stable 5
Important Caveats and Monitoring
Do not exceed 70 mg/day. This is the maximum FDA-approved dose, and research provides no efficacy data above this threshold 3. If 70 mg is insufficient, consider switching to an alternative medication or adding psychosocial interventions rather than exceeding the maximum dose 5.
Monitor cardiovascular parameters: Check blood pressure and pulse quarterly in adults on stimulants 5. Mean increases with Vyvanse are modest (pulse +2-3 bpm, systolic BP +1 mmHg, diastolic BP +1-2 mmHg) but individual responses vary 1.
Common side effects include decreased appetite (most common), dry mouth, insomnia, headache, and irritability 2. These are generally mild-to-moderate and consistent with long-acting stimulants. Weight loss and appetite suppression should be monitored at each visit 5.
Timing matters: Vyvanse should be taken in the morning to minimize insomnia. Its duration of action extends 12-14 hours, providing coverage through the workday and evening activities 4.
Special Consideration: Prior Stimulant Use
Prior pharmacotherapy does not affect dose-response. Research shows that LDX dose-response efficacy between 30-70 mg is independent of whether patients previously used other ADHD medications 3. Don't assume patients who failed other stimulants need higher Vyvanse doses—start at 30 mg and titrate based on response.